The type I interferon system is integral to human antiviral immunity. However, inappropriate stimulation or defective negative regulation of this system can lead to inflammatory disease. We sought to determine the molecular basis of genetically uncharacterized cases of the type I interferonopathy Aicardi-Goutières syndrome and of other undefined neurological and immunological phenotypes also demonstrating an upregulated type I interferon response. We found that heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (also called MDA5) cause a spectrum of neuroimmunological features consistently associated with an enhanced interferon state. Cellular and biochemical assays indicate that these mutations confer gain of function such that mutant IFIH1 binds RNA more avidly, leading to increased baseline and ligand-induced interferon signaling. Our results demonstrate that aberrant sensing of nucleic acids can cause immune upregulation.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gresser, I., Tovey, M.G., Maury, C. & Chouroulinkov, I. Lethality of interferon preparations for newborn mice. Nature 258, 76–78 (1975).
Gresser, I. et al. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263, 420–422 (1976).
Gresser, I. et al. Interferon-induced disease in mice and rats. Ann. NY Acad. Sci. 350, 12–20 (1980).
Crow, Y.J. Type I interferonopathies: a novel set of inborn errors of immunity. Ann. NY Acad. Sci. 1238, 91–98 (2011).
Crow, Y.J. et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat. Genet. 38, 917–920 (2006).
Crow, Y.J. et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat. Genet. 38, 910–916 (2006).
Rice, G.I. et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 41, 829–832 (2009).
Rice, G.I. et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243–1248 (2012).
Rice, G.I. et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 12, 1159–1169 (2013).
Briggs, T.A. et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43, 127–131 (2011).
Goubau, D., Deddouche, S. & Reis, E.S.C. Cytosolic sensing of viruses. Immunity 38, 855–869 (2013).
Peisley, A. et al. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc. Natl. Acad. Sci. USA 108, 21010–21015 (2011).
Peisley, A. et al. Kinetic mechanism for viral dsRNA length discrimination by MDA5 filaments. Proc. Natl. Acad. Sci. USA 109, E3340–E3349 (2012).
Wu, B. et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 152, 276–289 (2013).
Rice, G. et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutières syndrome. Am. J. Hum. Genet. 80, 811–815 (2007).
Tojo, K. et al. Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation. Mov. Disord. 21, 1510–1513 (2006).
Livingston, J.H. et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J. Med. Genet. 51, 76–82 (2014).
Kondo, T. et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J. Dermatol. 35, 662–666 (2008).
Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711–723 (2003).
Baechler, E.C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100, 2610–2615 (2003).
Cen, H. et al. Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Autoimmunity 46, 455–462 (2013).
Crampton, S.P., Deane, J.A., Feigenbaum, L. & Bolland, S. Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J. Immunol. 188, 1451–1459 (2012).
Nejentsev, S. et al. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324, 387–389 (2009).
Crow, Y.J. & Rehwinkel, J. Aicardi-Goutières syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 18, R130–R136 (2009).
Stetson, D.B. Endogenous retroelements and autoimmune disease. Curr. Opin. Immunol. 24, 692–697 (2012).
Deddouche, S. et al. Identification of an LGP2-associated MDA5 agonist in picornavirus-infected cells. eLife 3, e01535 (2014).
Funabiki, M. et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 40, 199–212 (2014).
Crow, Y.J. et al. Therapies in Aicardi-Goutières syndrome. Clin. Exp. Immunol. 175, 1–8 (2014).
Herries, D.G. Enzyme Structure and Mechanism 2nd edn. (W H Freeman, New York, 1985).
We sincerely thank the participating families for the use of genetic samples and clinical information and all clinicians who contributed samples and data not included in this manuscript. We thank D. Chase for proofreading the manuscript. We thank G. Notarangelo for helpful discussion. Y.d.T.D. holds a Novartis Foundation postdoctoral fellowship. S.H. holds a Pew scholarship and Career Development award from Boston Children's Hospital. Y.J.C. acknowledges the Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, the Greater Manchester Comprehensive Local Research Network, the Great Ormond Street Hospital Children's Charity, the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement 241779 and the European Research Council (GA 309449). The authors would like to thank the NHLBI GO ESP and its ongoing studies, which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the Women's Health Initiative (WHI) Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010).
The authors declare no competing financial interests.
Integrated supplementary information
Family number is shown above each pedigree. Sequence chromatograms are given where available. IFIH1 protein status is stated if known, with WT denoting wild type. De novo mutations are annotated in parentheses. Uncolored shapes represent unaffected individuals. Black-filled shapes represent clinically affected individuals. Gray-filled shapes represent clinically asymptomatic mutation-positive individuals. A diagonal line indicates deceased status. IS denotes interferon score (for participants with repeat samples, the mean combined measurement is given).
IFIH1 homologs were identified on Ensembl and aligned using CLUSTAL Omega. Amino acids altered by IFIH1 mutations are highlighted by a red box. H.Sapiens, Homo sapiens (ENSP00000263642); P.troglodytes, Pan troglodytes (ENSPTRG00000012582); M.mulatta, Macaca mulatta (ENSMMUG00000003202); R.Norvegicus, Rattus norvegicus (ENSRNOG00000006227); M.Musculus, Mus musculus (ENSMUSG00000026896); C.Familiaris, Canis familiaris (ENSCAFG00000010438); B.Taurus, Bos Taurus (ENSBTAG00000008142); G.gallus, Gallus gallus (ENSGALG00000011089); X.Tropicalis, Xenopus tropicalis (ENSXETG00000013176); T.nigroviridis, Tetraodon nigroviridis (ENSTNIG00000016500); D.Rerio, Danio rerio (ENSDARG00000018553). Homology to the human IFIH1 reference sequence (ENSP00000263642): human–P. troglodytes, 100%; human–M. mulatta, 98%; human–B. torus, 84%; human–C. familiaris, 83%; human–M. musculus, 80%; human–R. norvegicus, 80%; human–G. gallus, 56%; human–X. tropicalis, 55%; human–D. rerio, 49%; human–T. nigroviridis, 44%.
RNA helicases were identified on Ensembl and aligned using CLUSTAL Omega. Amino acids altered by IFIH1 mutations are highlighted by a red box. IFIH1 (ENSP00000263642), DDX58 (RIG-I) (ENSP00000369213), DHX58 (LGP2) (ENSP00000251642). Homology of human IFIH1 (reference sequence ENSP00000263642) to DDX58 (RIG-I) and DHX58 (LGP2) is 31% and 41%, respectively.
Supplementary Figure 4 Individual ISG transcript levels in IFIH1 mutation–positive individuals, their IFIH1 mutation–negative relatives and a cohort of 29 controls.
qPCR of a panel of six ISGs in whole blood measured in 5 families with mutations in IFIH1 and 29 healthy controls. RQ is equal to 2−ΔΔCt, with –ΔΔCt ± s.d. (i.e., the normalized fold change relative to a calibrator). Each value is derived from three technical replicates. For ease of presentation, mutation-negative relatives (n = 13) have been combined with the control cohort (M-NR+C) in this figure. Horizontal red bars show the median RQ value for each probe in each group. For individuals with repeat samples (biological replicates), all measurements are shown. Data were analyzed by one-way ANOVA using Dunnett's multiple-comparison test. ***P < 0.0001. Source data
About this article
Cite this article
Rice, G., del Toro Duany, Y., Jenkinson, E. et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 46, 503–509 (2014). https://doi.org/10.1038/ng.2933
Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib
Pediatric Rheumatology (2021)
Pediatric Neurology (2021)
Journal of Clinical Immunology (2021)